BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:With industry eagerly anticipating readouts from Merck and Mod erna’s Phase 3 trial of adjuvant V940 in combination with Keytruda\, BioN Tech\, and Genentech’s global trials for BNT116 for non-small cell lung c ancer\, we are advancing ever closer to a commercially approved personali zed cancer vaccine. Beyond mRNA\, though\, the field is expanding\, as no vel DNA\, peptide\, viral\, and cellular vaccines accelerate towards the clinic and showcase improvements in efficacy and safety.\n\nThe 2nd Annua l Personalized Cancer Vaccine Summit returns to Boston as the only strate gic forum dedicated to platforming the full spectrum of individualized ca ncer vaccines. We are arming this community with the means to accelerate the development of their personalized immunotherapies for cancer patients in need.\n\nWith granular insights from early discovery and preclinical efforts through to the optimization of clinical and manufacturing strateg ies\, it’s your one-stop shop to benchmark against competitors\, challeng es in efficacy\, cost-effectiveness\, and safety\, and hear the latest cl inical data poised to shape the field. Plus\, in-depth discussions and da ta-driven case studies showcase the breadth of modalities in development\ , from RNA\, Peptide\, and DNA through to Viral and Cellular\, enabling y ou to gain cross-modality learnings to improve your vaccine’s efficacy at the tumor level and ensure you select the right neoantigen type to set y our vaccine up for success.\n\nJoin 80+ CXOs\, VPs\, and Directors of Onc ology\, Immunotherapy\, and Vaccine R AND D from the field’s leading biop harma organizations to gain the insights and partners you require to tran slate your personalized vaccines into robust clinical candidates and comm ercially viable products for multiple tumor types.\n\n \;\n\nURLs:Tic kets: https://go.evvnt.com/3246149-1?pid=185 \;Brochure: https://go.e vvnt.com/3246149-3?pid=185 \;\n\nDate and Time: Tue\, 18 Nov 2025 08: 30 - Thu\, 20 Nov 2025 17:40\n\nVenue details: Revere Hotel Boston Common \, 200 Stuart Street\, Boston\, Massachusetts\, 02116\, United States\n\n Category: Conferences | Science\, Health &\; Medicine | Pharmaceutical s\n\nPrices:Conference + Focus Day (3 Day Pass) - Drug Developer Pricing: USD 4197.00\,Conference Only - Drug Developer Pricing: USD 2999.00\,Conf erence + Focus Day (3 Day Pass) - Academic Pricing: USD 3597.00\,Conferen ce Only - Academic Pricing: USD 2599.00\,Conference + Focus Day (3 Day Pa ss)- Solution Provider Pricing: USD 5097.00\,Conference Only - Solution P rovider Pricing: USD 3699.00\n\nSpeakers: Alan Rigby\, Chief Executive Of ficer\, Epitopea\, Ananta Paine\, Senior Associate\, Guide Point Insights \, Baochun Zhang\, Assistant Professor - Medicine\, Dana-Farber / Harvard Cancer Center\, Diego Silva\, Managing Director\, Vaxine\, Fernando Kreu tz\, Chief Executive Officer\, Cellvax\, Jean-francois Millau\, Co-Founde r and Chief Executive Officer\, Tatum Bioscience\, Jian Yan\, Vice Presid ent - Research and Discovery\, Geneos Therapeutics\, Inc.\, Joann Peters\ , Chief Operating Officer\, Geneos Therapeutics\, Inc.\, Kristen Dahlgren \, Chief Executive Officer and Founder\, Cancer Vaccine Coalition\, Lelia Delamarre\, Director - Cancer Immunology Research and Distinguished Scie ntist\, Genentech\, Lisa Butterfield\, Distinguished Scientist\, Merck an d Co\, Maurizio Ceppi\, Chief Scientific Officer\, Transgene\, Michelle B rown\, Vice President\, Moderna\, Nick Valiante\, Co-Founder and Chief Sc ientific Officer\, Innovac Therapeutics\, Ray Goodrich\, Chief Scientific Officer/Vice President of R AND D\, PhotonPharma\, Robert Dillman\, Chie f Medical Officer\, AiVita Biomedical\, Roy de Souza\, Co-Founder and Chi ef Executive Officer\, BreakBio\, Ruben Rizzi\, Senior Vice President - G lobal Regulatory Affairs\, BioNTech\, Sean Sullivan\, Vice President Tech nology Innovation and Development\, Arcturus Therapeutics\, Simone Steine r\, Chief Technology Officer\, Transgene\, Stephen Schoenberger\, Profess or\, La Jolla Institute for Immunology\, Vassiliki Karantza\, Associate V ice President - Clinical Research Oncology\, Merck and Co\, Vicki Norton\ , Chair of Life Science Division\, Duane Morris LLP\, Wolfgang Fischl\, C hief Executive Officer\, YGION Biomedical GmbH\n DTEND:20251120T174000 DTSTAMP:20260512T220335Z DTSTART:20251118T083000 LOCATION:Revere Hotel Boston Common\, 200 Stuart Street \, Boston\, Massa chusetts\, 02116\, SEQUENCE:0 SUMMARY:With industry eagerly anticipating readouts from Merck and Moderna ’s Phase 3 trial of adjuvant V940 in combination with Keytruda\, BioNTech \, and Gen... UID:119fee99-c45b-45f4-8a91-3e958c70658f END:VEVENT END:VCALENDAR